News & Events – Page 3 – Sumitovant

Select Company

February 11, 2021Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter Fiscal Year 2020
January 26, 2021Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership
January 26, 2021Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 26, 2021Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 06, 2021Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
January 04, 2021Sumitovant Biopharma Announces the Appointment of Industry Veteran, David Marek, as Chief Executive Officer of Myovant Sciences
January 04, 2021Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
December 28, 2020Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
December 28, 2020Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
December 23, 2020Sumitovant Biopharma Announces Urovant Sciences Receives U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
« Previous 1 2 3 4 5 … 17 Next »